While all Resolutions were passed with significant majorities, the Board notes that Resolutions 2 and 9 received less than 80% of votes cast in favor. The Board has consistently taken steps to ...
Maintained a strong financial position with $319.6M PureTech level cash, cash equivalents and short-term investments and $319.9M Consolidated cash, cash equivalents and short-term investments as of ...
PureTech Health(NASDAQ:PRTC) reported its second quarter 2025 earnings on Aug. 28, 2025, highlighting a cash balance of just under $320 million at the end of the first half of 2025, a reduction in ...
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, a ...
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and ...
PureTech Health plc (NASDAQ:PRTC) Q4 2024 Earnings Call Transcript April 30, 2025 PureTech Health plc beats earnings expectations. Reported EPS is $3.98, expectations were $-2.83. Operator: Greetings ...
The business has a fifty day moving average of $17.78 and a 200-day moving average of $18.06. An institutional investor recently raised its position in PureTech Health stock. Pentwater Capital ...
The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech Health” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Monday, June 16, 2025. All of the resolutions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results